Clinical trials: Myelogenous Leukemia, Acute
Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Acute myeloid leukemia Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death.
- Conditions
- Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)
- Trial name
- NCT07486726
- Testing
- Aclarubicin, Venetoclax, Azacitidine
- Where
- 4 sites in China
- Volunteers
- 112 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Elderly patients with acute myeloid leukemia (AML) often face unfavorable prognostic factors such as multiple comorbidities, adverse cytogenetic profiles, and pre-existing hematological disorders.
- Trial name
- NCT06571825
- Testing
- Venetoclax, Allogeneic transplant
- Where
- China
- Volunteers
- 118 people
- Sponsor
- He Huang
Acute Myeloid Leukemia
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
This is a single arm study to evaluate the safety and efficiency of azacitidine (AZA) combination with venetoclax and ATRA in Patients With Newly diagnosed acute myeloid leukemia.
- Trial name
- NCT05654194
- Testing
- Azacitidine Combined With Venetoclax and ATRA group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Myeloid
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
- Trial name
- NCT03080922
- Testing
- hematopoietic stem cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Leukemia, Myeloid, Acute
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation. The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the…
- Trial name
- NCT03720366
- Testing
- enasidenib, Arm 1 probes, Arm 2 Probes
- Where
- 10 sites in Australia, South Korea
- Volunteers
- 40 people
- Sponsor
- Celgene
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood…
- Conditions
- Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
- Trial name
- NCT02333162
- Testing
- Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Acute Myeloid Leukemia (AML)
Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1
1. Study Objectives To evaluate the effect of various clinical variables including HLA-disparity and NK cell-related variables, upon outcomes of allogeneic hematopoietic cell transplantation (HCT) using uniform conditioning…
- Trial name
- NCT07155382
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Asan Medical Center
AML, MDS
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
This study is a prospective, multicenter, open-label umbrella clinical study planned to enroll 126 subjects with acute myeloid leukemia/myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT06972641
- Testing
- Decitabine, Sorafenib (BAY-43-9006)，giritinib, Avastinib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Ruijin Hospital
Myeloid Malignancy, Myelodysplastic Syndromes
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies.
- Conditions
- Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia
- Trial name
- NCT05455294
- Testing
- Navitoclax, Venetoclax, Decitabine
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Jacqueline Garcia, MD
Leukemia, Myeloid, Acute
Post-transplant Flotetuzumab for AML
The purpose of this research study is to determine if the study drug, flotetuzumab, is safe and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed after transplant.
- Trial name
- NCT05506956
- Testing
- Flotetuzumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture
Acute Myeloid Leukemia
Expanded Access to ABBV-787
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-787 prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT06439966
- Testing
- ABBV-787
- Sponsor
- AbbVie
Leukemia, Lymphoma
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002502
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid, Acute
ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia
Adult acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy associated with poor prognosis, especially after relapse.
- Trial name
- CeGAL (NCT02619071)
- Testing
- Tumor sampling, Constiutional DNA sampling
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Institut Paoli-Calmettes
Leukemia, Promyelocytic, Acute
Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database
Acute promyelocytic leukemia (APL) is a very rare type of leukemia. Because it is so rare, many doctors do not have experience treating it. APL has been shown to be curable most of the time.
- Trial name
- NCT02309333
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- Emory University
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.
Acute Myeloid Leukemia (AML) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation.
- Trial name
- NCT06786299
- Testing
- RD-IIT-001, CD84-CART
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia
Amonafide in Combination With Cytarabine in Secondary AML
This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
- Trial name
- NCT00273884
- Testing
- Amonafide L-Malate, Cytarabine
- Where
- 21 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Xanthus Pharmaceuticals, Inc.
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
This research study is for subjects that are receiving a bone marrow transplant. As part of the transplant subjects will receive stem cells from a donor who has agreed to donate stem cells for them.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- TAR (NCT01611298)
- Testing
- Tetanus
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Robert Krance
Leukemia, Myeloid, Acute
Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)
To investigate safety, tolerability of cafusertib combination with low dose cytarabine (LD-Ara-C) in Chinese patients with relapsed/refractory AML that are not eligible for conventional or intensive treatment.
- Trial name
- NCT02140606
- Testing
- Cafusertib Hydrochloride
- Where
- China
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.